NCT00236353 – An Open-label Study of the Efficacy and Safety of RISPERDAL Long-acting Microspheres (RISPERDAL CONSTA) Administered Once Monthly in Adults With Schizophrenia or Schizoaffective Disorder Posted on March 18, 2019 by tsuperadmin -
NCT00992407 – A Randomized, Open-label, Active-controlled Study to Evaluate Social Functioning of Long Acting Injectable Risperidone and Oral Risperidone in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder Posted on March 18, 2019 by tsuperadmin -
NCT00269919 – Effect on Efficacy, Safety and Quality of Life by Long-Term Treatment of Long-Acting Risperidone Microspheres in Patients With Schizophrenia Posted on March 18, 2019 by tsuperadmin -
NCT00216528 – A Prospective, Open-Label Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres (Risperdal Consta) Posted on March 18, 2019 by tsuperadmin -
NCT00086112 – A Double-blind, Randomized, Prospective Study to Evaluate Adjunctive Risperidone Versus Adjunctive Placebo in Generalized Anxiety Disorder Sub-optimally Responsive to Standard Psychotropic Therapy Posted on December 20, 2018 by tsuperadmin -
NCT01050582 – Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs Posted on December 20, 2018 by tsuperadmin -
NCT00576732 – Risperidone in the Treatment of Children and Adolescents With Autistic Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety, Followed by an Open-Label Extension Study of Safety Posted on December 20, 2018 by tsuperadmin -
NCT00236379 – A Six-month, Double-blind, Randomized, International, Multicenter Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects With Schizophrenia or Schizoaffective Disorder Posted on December 20, 2018 by tsuperadmin -
NCT00216632 – Treatment Success in Patients Requiring Treatment Change From Olanzapine to Risperidone Long Acting Injectable (TRESOR) Posted on December 20, 2018 by tsuperadmin -
NCT00369239 – Is Premorbid Functioning a Predictor of Outcome in Patients With Early Onset Psychosis Treated With Risperdal Consta? Posted on December 20, 2018 by tsuperadmin -